Search

Viatris Inc

Gesloten

SectorGezondheidszorg

16.23 1.18

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

15.85

Max

16.26

Belangrijke statistieken

By Trading Economics

Inkomsten

-295M

-119M

Verkoop

240M

3.8B

EPS

0.69

Dividendrendement

2.92

Winstmarge

-3.162

Werknemers

30,000

EBITDA

9.4M

653M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+13.28% upside

Dividenden

By Acuity

Dividendrendement

Sectorgemiddelde

2.92%

2.22%

Volgende Winsten

5 nov 2026

Volgende dividenddatum

16 sep 2026

Volgende Ex Dividend datum

21 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.8B

19B

Vorige openingsprijs

15.05

Vorige sluitingsprijs

16.23

Nieuwssentiment

By Acuity

50%

50%

163 / 340 Rangschikking in Healthcare

Viatris Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 20:06 UTC

Viatris Inc shares are higher today, despite earlier session pullbacks. Broader market sentiment is mixed following a decline in U.S. retail sales.

13 aug 2026, 20:06 UTC

Viatris Inc shares are lower today, reflecting broader market trends amid rising U.S. jobless claims that exceeded expectations. The stock remains near its one-month range low.

12 aug 2026, 23:06 UTC

Viatris Inc. shares moved higher in after-market trading, recovering from earlier losses. The stock remains below its 20-day moving average.

11 aug 2026, 23:41 UTC

Viatris Inc. shares rose in after-market trading, despite earlier fluctuations and broader market concerns about inflationary pressures and oil prices.

10 aug 2026, 19:42 UTC

Pharmaceuticals sector strength is lifting Viatris Inc during Monday's session, with increased trading volume contributing to the upward movement.

7 aug 2026, 22:01 UTC

Viatris Inc. shares are higher in after-market trading, supported by a broader equity rally following weaker employment data and reduced interest rate hike concerns.

6 aug 2026, 23:01 UTC

Viatris Inc shares are higher in after-market hours, recovering from earlier lows. The stock is trading above Thursday's close despite recent declines.

5 aug 2026, 23:11 UTC

Viatris Inc. shares are trading higher in after-market hours, recovering significantly above the 20-day moving average amid broader market optimism despite no specific news.

4 aug 2026, 23:06 UTC

Viatris Inc shares are higher in after-market trading, reflecting positive momentum and positioning above the 20-day moving average. No specific news was identified.

3 aug 2026, 20:06 UTC

Viatris Inc shares are higher today, reflecting broader market gains led by major stocks. The S&P 500 and Nasdaq 100 have also risen.

31 jul 2026, 21:02 UTC

Viatris Inc shares are lower in after-market hours, continuing a four-session decline amid rising inflation concerns and higher crude oil prices.

30 jul 2026, 18:56 UTC

Event

Viatris shares are trading lower despite FDA approval of the Gwyn Lo contraceptive patch. Broader economic data may be impacting the stock's performance.

29 jul 2026, 22:03 UTC

Event

Viatris Inc. shares are lower in after-market hours despite FDA approval of the Gwyn Lo contraceptive patch, amid broader market caution over geopolitical tensions.

28 jul 2026, 19:36 UTC

Social Media

Viatris shares are higher today, supported by strong sector gains and a significant rise in January 2027 $10 call options activity.

27 jul 2026, 19:11 UTC

Viatris Inc shares are higher today, breaking a trend of daily gains. No specific news was identified to explain this movement.

23 jul 2026, 20:06 UTC

Viatris Inc's shares are higher during Thursday's session, continuing an upward trend since Wednesday's close. No specific news was identified to explain the movement.

22 jul 2026, 23:16 UTC

Viatris Inc shares are higher in after-market hours, recovering from an earlier dip and reflecting strength amid rising crude oil prices.

21 jul 2026, 18:46 UTC

Viatris Inc shares are higher today, rebounding after an earlier dip amid a broader recovery in U.S. markets and renewed investor optimism.

20 jul 2026, 19:21 UTC

News

Viatris Inc shares are lower amid negative sentiment in the Pharmaceuticals sector. Analysts cite a price target of $17.81, reflecting concerns over sales declines.

Peer Vergelijking

Prijswijziging

Viatris Inc Prognose

Koersdoel

By TipRanks

13.28% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.17 USD  13.28%

Hoogste 23 USD

Laagste 12 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Viatris Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

6 ratings

2

Buy

3

Hold

1

Sell

Sentiment

By Acuity

163 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat